Last reviewed · How we verify
SCM-AGH
At a glance
| Generic name | SCM-AGH |
|---|---|
| Sponsor | SCM Lifescience Co., LTD. |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Long-term Safety Follow-up Study of SCM-AGH in Patients Who Completed SCM-APT2001 Study
- Safety and Efficacy of SCM-AGH in Patients With Moderate to Severe Acute Pancreatitis (PHASE1, PHASE2)
- Safety and Efficacy of SCM-AGH in Subjects With Moderate to Severe Atopic Dermatitis (PHASE1, PHASE2)
- Long-Term Safety Follow-Up Study of SCM-AGH in Subjects Who Participated and Administered SCM-AGH in to Severe Atopic Dermatitis Clinical Trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SCM-AGH CI brief — competitive landscape report
- SCM-AGH updates RSS · CI watch RSS
- SCM Lifescience Co., LTD. portfolio CI